Scopus Biopharma Financials
Based on the key measurements obtained from Scopus Biopharma's financial statements, Scopus Biopharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.
With this module, you can analyze Scopus financials for your investing period. You should be able to track the changes in Scopus Biopharma individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Scopus |
The data published in Scopus Biopharma's official financial statements typically reflect Scopus Biopharma's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Scopus Biopharma's quantitative information. For example, before you start analyzing numbers published by Scopus accountants, it's essential to understand Scopus Biopharma's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the imprecision that can be found in Scopus Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Scopus Biopharma. Check Scopus Biopharma's Beneish M Score to see the likelihood of Scopus Biopharma's management manipulating its earnings.
Scopus Biopharma Stock Summary
Scopus Biopharma competes with Scpharmaceuticals, DiaMedica Therapeutics, Monopar Therapeutics, Pasithea Therapeutics, and Protara Therapeutics. Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York. Scopus Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Specialization | Healthcare, Biotechnology |
| Instrument | USA OTC Stock View All |
| Exchange | OTCMKTS Exchange |
| ISIN | US8091711015 |
| CUSIP | 809171101 |
| Location | New York; U.S.A |
| Business Address | 420 Lexington Avenue, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | scopusbiopharma.com |
| Phone | 212 479 2513 |
| Currency | USD - US Dollar |
Scopus Biopharma Key Financial Ratios
There are many critical financial ratios that Scopus Biopharma's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Scopus Biopharma reports annually and quarterly.| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 | ||||
| Target Price | 12.0 | ||||
| Beta | 1.16 | ||||
| Z Score | -9.9 |
Scopus Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Scopus Biopharma's current stock value. Our valuation model uses many indicators to compare Scopus Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Scopus Biopharma competition to find correlations between indicators driving Scopus Biopharma's intrinsic value. More Info.Scopus Biopharma is rated below average in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Scopus Biopharma's earnings, one of the primary drivers of an investment's value.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |